Cell2Cure
  • Home
  • The Company
  • Research, Technology and IP
    • Background
  • Clinical
  • Investor and Partners
  • News
  • Contact us
Select Page

The Danish Medicines Agency has approved the phase I clinical trial with cell treatment of children with autism and leaky gut syndrome

by Backoffice | Nov 30, 2022 | Trial results

The Danish Medicines Agency has November 23rd, 2022, approved the un-blinded phase I dose-titrating clinical trial where children with autism and signs of leaky gut syndrome are treated with allogeneic adipose-derived mesenchymal stem cells (ASCs). The children will...

Ethical approval for the ASC phase I clinical trial in children with autism and leaky gut syndrome

by Backoffice | Nov 4, 2022 | Studies and testing

The Danish National Center for Ethics has November 2nd, 2022, approved the un-blinded phase I clinical trial with dose-titrating of allogeneic adipose-derived mesenchymal stem cells (ASCs) for treatment of children with autism. The project is a collaboration between...

Cell2Cure has received approval from the Danish Medicinal Agency for a clinical Phase I study

by Backoffice | Sep 21, 2022 | Studies and testing

Cell2Cure will be investigating treatment of patients with diabetic foot ulcus with C2C_ASC. The clinical study will be carried out in collaboration with Professor Ole Lander Svendsen and his team at Bispebjerg University Hospital, Copenhagen, Denmark. The study was...

The Cell2Cure core technology has been granted patent rights in Australia

by Backoffice | Aug 21, 2022 | Patents

As of the 24th of March 2022, the patent secures C2Cs technological concept for industrial production, upscaling, and distribution of ASC products in Australia (Patent number: 2016342387). The patent “STEM CELL THERAPY BASED ON ADIPOSE-DERIVED STEM CELLS” has...

Patient enrollment finalized in the Phase II trial testing ASC in Sjögren’s syndrome

by Backoffice | Jun 17, 2022 | Studies and testing

Aqueous Deficient Dry Eye Disease, Sjögren’s syndrome is a serious autoimmune disease that can cause serious eye and vision problems due to reduced tear production. The patient enrollment is now finalized in the randomized double-blind placebo-controlled phase II...
« Older Entries

Recent Posts

  • The Danish Medicines Agency has approved the phase I clinical trial with cell treatment of children with autism and leaky gut syndrome
  • Ethical approval for the ASC phase I clinical trial in children with autism and leaky gut syndrome
  • Cell2Cure has received approval from the Danish Medicinal Agency for a clinical Phase I study
  • The Cell2Cure core technology has been granted patent rights in Australia
  • Patient enrollment finalized in the Phase II trial testing ASC in Sjögren’s syndrome

Recent Comments

    Archives

    • November 2022
    • September 2022
    • August 2022
    • June 2022
    • April 2022
    • February 2022
    • July 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020
    • January 2020

    Categories

    • Collaborations
    • Patents
    • Studies and testing
    • Trial results

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    © 2021 Cell2Cure | CVR.no 39401975 | Designed by ICR-Design ApS